NICE recommends Gazyvaro (obinutuzumab) plus bendamustine chemotherapy to treat follicular lymphoma.- Roche
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending that use of Gazyvaro (obinutuzumab) from Roche, to treat follicular lymphoma in combination with bendamustine (chemotherapy) followed by Gazyvaro maintenance for patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab (MabThera) or a rituximab-containing regimen.
NICE considered that the Gazyvaro-based approach is clinically effective, but were uncertain of its overall survival gain, and so recommended its use in the Cancer Drugs Fund where further evidence can be collected.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.